AmgenvsUltragenyx Pharmaceutical

AMGN and RARE stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$438.82

Value $237B

-1.14%
AMGN's page

RARE

Ultragenyx Pharmaceutical Inc.

$17.22

Value $1.8B

-2.88%
RARE's page

Amgen (AMGN) has a market value of $237B and Ultragenyx Pharmaceutical (RARE) $1.8B. Over the last year, with dividends, AMGN moved +31.1% and RARE -47.5%. Dividend yield: AMGN 2.27%, RARE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$237B

    RARE$1.8B

    AMGN is 135 times RARE

  • Revenue, 12 months

    AMGN$38.9B

    RARE$730M

    AMGN is 53 times RARE

  • Net income, 12 months

    AMGN$9.4B

    RARE-$524M

  • Operating margin

    AMGN32.4%

    RARE-64.0%

    96.4 points apart

  • ROIC

    AMGN16.2%

    RARE–

  • P/E

    AMGN25.2

    RARE–

  • Dividend yield

    AMGN2.3%

    RARE0.0%

    2.3 points apart

  • 5-year return

    AMGN+149.2%

    RARE-77.7%

    226.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+149.2%

RARE-77.7%

10020020222023202420252026
Returns by period
PeriodAMGNWith dividendsRAREWith dividends
1 year since November 18, 2025+31.1%Price +27.6%-47.5%Price -47.5%
3 years since November 17, 2023+79.5%+21.5% a yearPrice +65.3%-56.9%-24.5% a yearPrice -56.9%
5 years since November 18, 2021+149.2%+20.0% a yearPrice +115.1%-77.7%-26.0% a yearPrice -77.7%
10 years since November 21, 2016+303.3%+15.0% a yearPrice +201.5%-79.7%-14.7% a yearPrice -79.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenRAREUltragenyx Pharmaceutical

Valuation

AMGNRARE
Valuation
Price$438.82$17.22
Market value$237B$1.8B
Enterprise value (EV)$277B$1.5B
P/E25.2–
P/E, 5-year median23.0–
P/B16.5–
EV/EBIT22.0–
Free cash flow yield4.1%–

Results and growth

AMGNRARE
Results and growth
Revenue, 12 months$38.9B$730M
Net income, 12 months$9.4B-$524M
Free cash flow, 12 months$9.6B-$442M
Earnings per share, 12 months$17.25-$5.18
Revenue growth, year on year10.0%20.2%
Revenue growth a year, past+7.6%over 5 years+20.0%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNRARE
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%-64.0%
Net margin24.1%-71.8%
ROIC16.2%–
ROE87.8%–

Balance sheet

AMGNRARE
Balance sheet
Cash$13.2B$266M
Total debt$54.0B$36M
Net debt / EBITDA2.3–
Interest cover4.8×–

Dividends and buybacks

AMGNRARE
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or RARE

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Ultragenyx Pharmaceutical?

By market value, Amgen ($237B) is about 134.8 times Ultragenyx Pharmaceutical ($1.8B), at today's prices.

How did AMGN and RARE stock do over the last 10 years?

Since November 21, 2016, AMGN's price moved +201.5% and RARE's -79.7%. With dividends: AMGN +303.3% (+15.0% a year), RARE -79.7% (-14.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or RARE?

The dividend yield at today's price is 2.27% for Amgen and none for Ultragenyx Pharmaceutical. Over the last twelve months they paid $9.94 and – per share.

Which has the higher profit margins, Amgen or Ultragenyx Pharmaceutical?

Over the last twelve months, the net margin was 24.1% for Amgen and -71.8% for Ultragenyx Pharmaceutical, and the operating margin 32.4% and -64.0%. Revenue was $38.9B and $730M.

Which is the better investment, Amgen or Ultragenyx Pharmaceutical?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.